| budesonide/formoterol / Generic mfg. |
2020-001713-20: Efficacy and safety of budesonide/formoterol versus terbutaline nebulization to treat children having an asthma attack Efficacité et sécurité du budenoside/formoterol par rapport à la terbutaline pour traiter les enfants ayant une crise d'asthme |
|
|
| Not yet recruiting | 3 | 102 | Europe | , Inhalation powder, pre-dispensed, Bricanyl, Symbicort | Centre Hospitalier Intercommunal de Créteil, Astrazeneca | moderate asthma exacerbation exacerbation modérée d'asthme, asthma crisis crise d'asthme, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
ACTRN12622001217796: A Randomised Controlled Trial of the efficacy and safety of an Inhaled Corticosteroid and Long Acting Beta Agonist maintenance and/or reliever therapy versus standard maintenance with separate reliever therapy in children with mild, moderate and severe asthma. |
|
|
| Recruiting | 3 | 400 | | | Medical Research Institute of New Zealand, AstraZeneca Ltd | Asthma | | | | |
ChiCTR-TRC-08000215: Chronic obstructive pulmonary disease(COPD)--Symbicort Turbuhaler clinical study |
|
|
| Completed | 3 | 450 | | Symbicort? 160/4.5ug/breathing, 2 breathing/time, 2 times/day+Symbicort?160/4.5ug/breathing, prn ;Symbicort 160/4.5ug/breathing, 2 breathing/time, 2 times/day + Turbuhaler 100ug/breathing, prn ;Si Lihua 18ug/breathing, 1 breathing/time, 1 time/day + Auccitub 12ug/breathing, 2 times/day, and Turbuhaler 100ug/breathing, prn | The First Affiliated Hospital of Sun Yat-sen University; 2nd and 3rd Affiliated Hospital of SYSU, Department of Statistics of School of Public Health of SYSU, Sun Yat-sen University | Chronic obstructive pulmonary disease(COPD) | | | | |
| Completed | 3 | 450 | | one inhalation of Pulmicort Turbuhaler 200 ug/inhalation ;Oxis Turbuhaler 4.5 ug/inhalation with symptom-driving ;Symbicort Turbuhaler 160/4.5 ug/inhalation with symptom-driving | 1st Affiliated Hospital of SYSU; 2nd and 3rd Affiliated Hospital of SYSU, 1st Affiliated Hospital of SYSU | mild asthma | | | | |
2013-003073-10: A 24 week study (with an extension to 52 weeks in a proportion of subjects) to compare the safety and effectiveness of FF/UMEC/VI with budesonide/formoterol in subjects with COPD Studio di 24 settimane (con estensione a 52 settimane in un sottogruppo di soggetti) per confrontare la sicurezza e l’efficacia di FF/UMEC/VI vs. budesonide/formoterolo in soggetti con broncopneumopatia cronica ostruttiva. |
|
|
| Ongoing | 3 | 200 | Europe | Fluticasone Furoate/Umeclidinium/Vilanterol, SALBUTAMOLO, GSK2834425, SB-240563, Symbicort Turbohaler 400 micrograms/12 micrograms/inhalation, inhalation powder, VENTOLIN SOSP INAL 200D 100MCG, Symbicort Turbohaler 400 micrograms/12 micrograms/inhalation, inhalation powder, VENTOLIN SOSP INAL 200D 100MCG | GlaxoSmithKline Research and Development, GlaxoSmithKline | Chronic Obstructive Pulmonary Disease | | | | |
2015-002384-42: Randomised Controlled Trial of the efficacy and safety of an ICS (Inhaled Corticosteroid)/LABA (long-acting beta agonist) reliever therapy regimen in asthma. |
|
|
| Ongoing | 3 | 675 | Europe | Symbicort® Turbohaler® 200 micrograms/6 micrograms/inhalation, inhalation powder, Pulmicort® Turbohaler® 200, Ventolin® Evohaler® 100 micrograms, N/A, Inhalation powder, Pressurised inhalation, Symbicort® Turbohaler® 200 micrograms/6 micrograms/inhalation, inhalation powder, Pulmicort® Turbohaler® 200, Ventolin Inh. CFC free 100 micrograms | Medical Research Institute of New Zealand, Astra Zeneca | Asthma., Asthma., Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
ASTHMAFAST, NCT04705727: Budesonide/Formoterol Turbuhaler® Versus Terbutaline Nebulization as Reliever Therapy in Children With Moderate Asthma Exacerbation |
|
|
| Terminated | 3 | 102 | Europe | Budesonide Formoterol Drug Combination, nebulisation of terbutaline | Centre Hospitalier Intercommunal Creteil, AstraZeneca | Asthma in Children | 09/21 | 06/23 | | |
NCT05322707: BE Study Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg Inhalation Product in Asthma Patient |
|
|
| Completed | 3 | 1485 | US | Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg, Test product, Symbicort, 80 Mcg-4.5 Mcg/Inh Inhalation Aerosol, RLD, Placebo, Placebo for Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg | Cipla Ltd. | Asthma | 08/23 | 08/23 | | |
VATHOS, NCT05202262 / 2021-002026-24: A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma |
|
|
| Recruiting | 3 | 630 | Europe, Canada, Japan, US, RoW | BFF MDI 320/9.6 μg, BFF, BFF MDI 160/9.6 μg, BD MDI 320 μg, BD, Open-label Symbicort TBH 320/9 μg, Symbicort TBH | AstraZeneca | Asthma | 03/25 | 03/25 | | |
ARRIVAL, NCT06473779: Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. |
|
|
| Not yet recruiting | 3 | 300 | NA | Tezepelumab, TEZSPIRE®, Budesonide/formoterol, SYMBICORT® pMDI, Albuterol/budesonide (AIRSUPRA®), AIRSUPRA®, Mannitol, ARIDOL®, Salbutamol, Sabumalin, albuterol, ventolin HFA, Proair HFA, Proventil HFA | AstraZeneca, Fortrea | Severe Asthma | 06/27 | 06/27 | | |
| Recruiting | 3 | 2200 | Europe, Canada, Japan, US, RoW | BGF MDI 320/28.8/9.6 μg, BGF, BGF MDI 320/14.4/9.6 μg, BFF MDI 320/9.6 μg, BFF, BFF pMDI 320/9 μg, Symbicort® | AstraZeneca | Asthma | 03/25 | 03/25 | | |
| Recruiting | 3 | 2200 | Europe, US, RoW | BGF MDI 320/28.8/9.6 μg, BGF, BGF MDI 320/14.4/9.6 μg, BFF MDI 320/9.6 μg, BFF, BFF pMDI 320/9 μg, Symbicort® | AstraZeneca | Asthma | 03/25 | 03/25 | | |
